Bulletin
Investor Alert

Market Pulse Archives

April 22, 2021, 3:37 p.m. EDT

FDA approves GSK's endometrial cancer therapy

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    GlaxoSmithKline PLC ADR (GSK)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

U.S.-listed shares of GlaxoSmithKline /zigman2/quotes/209463850/composite GSK -0.08% were down 1.4% in trading on Thursday after the Food and Drug Administration said it had granted accelerated approval to the company's endometrial cancer treatment. The immunotherapy, which was called dostarlimab and is now named Jemperli, is approved to treat patients with severe forms of this kind of cancer who have a genetic feature known as dMMR. About one-quarter of patients with this kind of cancer have dMMR tumors, the FDA said in a statement. A clinical trial with 71 participants found that Jemperli got rid of or reduced dMMR tumors in 42% of the patients. The regulator also said that additional trials are needed to back up the clinical data -- the approval is an "accelerated" decision based on unmet need -- and those studies are already underway. A GSK spokesperson did not immediately respond to a request for Jemperli's price. GSK's stock has gained 2.4% so far this year, while the S&P 500 /zigman2/quotes/210599714/realtime SPX -0.85% is up 10.2%.

/zigman2/quotes/209463850/composite
US : U.S.: NYSE
$ 39.56
-0.03 -0.08%
Volume: 4.47M
May 18, 2021 4:00p
P/E Ratio
14.66
Dividend Yield
5.06%
Market Cap
$97.29 billion
Rev. per Employee
$464,855
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,127.83
-35.46 -0.85%
Volume: 2.33B
May 18, 2021 5:16p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.